Top

BMC Dermatology

Published in:

Open Access 01-12-2017 | Study protocol

Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face − protocol of a multicenter, prospective, randomized, controlled, two-armed study

Authors: E. Kohl, M. Koller, F. Zeman, R.-M. Szeimies, W. G. Philipp-Dormston, W. Prager, P. A. Gerber, S. Karrer

Published in: BMC Dermatology | Issue 1/2017

Abstract

Background

Photodynamic therapy with daylight (DL-PDT) is efficacious in treating actinic keratosis (AK), but the efficacy of field-directed, repetitive DL-PDT for the treatment and prophylaxis of AK in photodamaged facial skin has not yet been investigated.

Methods/design

In this multicenter, prospective, randomized, controlled, two-armed, observer-blinded trial, patients with a minimum of 5 mild-to-moderate AK lesions on photodamaged facial skin are randomly allocated to two treatment groups: DL-PDT with methyl aminolevulinate (MAL) and cryosurgery. In the DL-PDT group (experimental group), 5 treatments of the entire face are conducted over the course of 18 months. After preparation of the lesion and within 30 min after MAL application, patients expose themselves to daylight for 2 h. In the control group, lesion-directed cryosurgery is conducted at the first visit and, in the case of uncleared or new AK lesions, also at visits 2 to 5. The efficacy of the treatment is evaluated at visits 2 to 6 by documenting all existing and new AK lesions in the face. Cosmetic results and improvement of photoaging parameters are evaluated by means of a modified Dover scale.

Primary outcome parameter is the cumulative number of AK lesions observed between visits 2 and 6.

Secondary outcome parameters are complete clearance of AK, new AK lesions since the previous visit, cosmetic results independently evaluated by both patient and physician, patient-reported pain (visual analogue scale), patient and physician satisfaction scores with cosmetic results, and patient-reported quality of life (Dermatology Life Quality Index). Safety parameters are also documented (adverse events and serious adverse events).

Discussion

This clinical trial will assess the efficacy of repetitive DL-PDT in preventing AK and investigate possible rejuvenating effects of this treatment. (Trial registration: ClinicalTrials.gov Identifier: NCT02736760).

Trial registration

ClinicalTrials.gov Identifier: NCT02736760. Study Code Daylight_01. EudraCT 2014–005121-13.

Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T. Prevalence and risk factors of actinic keratoses in Germany--analysis of multisource data. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014;28(3):309–13.CrossRefPubMed

Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam study. The Journal of investigative dermatology. 2013;133(8):1971–8.CrossRefPubMed

Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177(2):350–8.CrossRefPubMed

Rowert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, Sterry W, Stockfleth E. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl 3):8–12.CrossRefPubMed

Callen JP, Bickers DR, Moy RL. Actinic keratoses. J Am Acad Dermatol. 1997;36(4):650–3.CrossRefPubMed

Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795–7.CrossRefPubMed

Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? European journal of dermatology : EJD. 2006;16(4):335–9.PubMed

Diepgen TL, Brandenburg S, Aberer W, Bauer A, Drexler H, Fartasch M, John SM, Krohn S, Palfner S, Romer W, et al. Skin cancer induced by natural UV-radiation as an occupational disease-requirements for its notification and recognition. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2014;12(12):1102–6.PubMed

Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, Gupta AK, Jacobs A, Kerl H, Lim HW, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - international league of dermatological societies in cooperation with the European dermatology forum - short version. Journal of the European Academy of Dermatology and Venereology : JEADV. 2015;29(11):2069–79.CrossRefPubMed

10.

Wiegell SR, Fabricius S, Gniadecka M, Stender IM, Berne B, Kroon S, Andersen BL, Mork C, Sandberg C, Ibler KS, et al. Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study. Br J Dermatol. 2012;166(6):1327–32.CrossRefPubMed

11.

Lacour JP, Ulrich C, Gilaberte Y, Von Felbert V, Basset-Seguin N, Dreno B, Girard C, Redondo P, Serra-Guillen C, Synnerstad I, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. Journal of the European Academy of Dermatology and Venereology : JEADV. 2015;29(12):2342–8.CrossRefPubMed

12.

Rubel DM, Spelman L, Murrell DF, See JA, Hewitt D, Foley P, Bosc C, Kerob D, Kerrouche N, Wulf HC, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;

13.

Neittaanmaki-Perttu N, Karppinen TT, Gronroos M, Tani TT, Snellman E. Daylight photodynamic therapy for actinic keratoses: a randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate. Br J Dermatol. 2014;171(5):1172–80.CrossRefPubMed

14.

Wiegell SR, Fabricius S, Stender IM, Berne B, Kroon S, Andersen BL, Mork C, Sandberg C, Jemec GB, Mogensen M, et al. A randomized, multicentre study of directed daylight exposure times of 1(1/2) vs. 2(1/2) h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol. 2011;164(5):1083–90.CrossRefPubMed

15.

Zane C, Capezzera R, Sala R, Venturini M, Calzavara-Pinton P. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med. 2007;39(3):203–9.CrossRefPubMed

16.

Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol. 2005;141(10):1247–52.CrossRefPubMed

17.

Szeimies RM, Stockfleth E, Popp G, Borrosch F, Bruning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol. 2010;162(2):410–4.CrossRefPubMed

18.

Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol. 2006;86(1):25–8.PubMed

19.

Togsverd-Bo K, Omland SH, Wulf HC, Sorensen SS, Haedersdal M. Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: a randomized controlled trial. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2015;15(11):2986–90.CrossRef

20.

Wennberg AM, Stenquist B, Stockfleth E, Keohane S, Lear JT, Jemec G, Mork C, Christensen E, Kapp A, Solvsten H, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation. 2008;86(3):423–9.CrossRefPubMed

21.

Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol. 2010;162(1):171–5.CrossRefPubMed

22.

Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic photorejuvenation. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 2002;28(8):742–4. discussion 744

23.

Piccioni A, Fargnoli MC, Schoinas S, Suppa M, Frascione P, Ginebri A, Chimenti S, Peris K. Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. The Journal of dermatological treatment. 2011;22(5):247–53.CrossRefPubMed

24.

Sanclemente G, Medina L, Villa JF, Barrera LM, Garcia HI. A prospective split-face double-blind randomized placebo-controlled trial to assess the efficacy of methyl aminolevulinate + red-light in patients with facial photodamage. Journal of the European Academy of Dermatology and Venereology : JEADV. 2011;25(1):49–58.CrossRefPubMed

25.

Kohl E, Karrer S. New developments in photodynamic therapy. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2013;64(5):363–9.CrossRefPubMed

26.

Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol. 2010;62(1):85–95.CrossRefPubMed

27.

Szeimies RM, Torezan L, Niwa A, Valente N, Unger P, Kohl E, Schreml S, Babilas P, Karrer S, Festa-Neto C. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol. 2012;167(1):150–9.CrossRefPubMed

28.

Orringer JS, Hammerberg C, Hamilton T, Johnson TM, Kang S, Sachs DL, Fisher G, Voorhees JJ. Molecular effects of photodynamic therapy for photoaging. Arch Dermatol. 2008;144(10):1296–302.CrossRefPubMed

29.

Issa MC, Pineiro-Maceira J, Vieira MT, Olej B, Mandarim-de-Lacerda CA, Luiz RR, Manela-Azulay M. Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 2010;36(1):39–48.CrossRef

30.

Bagazgoitia L, Cuevas Santos J, Juarranz A, Jaen P. Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol. 2011;165(1):144–51.CrossRefPubMed

31.

Thai KE, Fergin P, Freeman M, Vinciullo C, Francis D, Spelman L, Murrell D, Anderson C, Weightman W, Reid C, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43(9):687–92.CrossRefPubMed

32.

Zouboulis CC, Rohrs H. Cryosurgical treatment of actinic keratoses and evidence-based review. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2005;56(4):353–8.CrossRefPubMed

33.

Krutmann J, Berking C, Berneburg M, Diepgen TL, Dirschka T, Szeimies M. New strategies in the prevention of actinic keratosis: a critical review. Skin Pharmacol Physiol. 2015;28(6):281–9.CrossRefPubMed

34.

Drago F, Ciccarese G, Parodi A. Nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2016;374(8):789–90.CrossRefPubMed

Title: Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face − protocol of a multicenter, prospective, randomized, controlled, two-armed study
Authors: E. Kohl
M. Koller
F. Zeman
R.-M. Szeimies
W. G. Philipp-Dormston
W. Prager
P. A. Gerber
S. Karrer
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Dermatology / Issue 1/2017
Electronic ISSN: 1471-5945
DOI: https://doi.org/10.1186/s12895-017-0064-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face − protocol of a multicenter, prospective, randomized, controlled, two-armed study

Abstract

Background

Methods/design

Discussion

Trial registration

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods/design

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2017

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial

A case report of erythroderma in a patient with borderline leprosy on reversal reaction: a result of the exacerbated reaction?

Expression profiling and bioinformatic analyses suggest new target genes and pathways for human hair follicle related microRNAs

Prevalence of head lice infestation and pediculicidal effect of permethrine shampoo in primary school girls in a low-income area in southeast of Iran

Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR)

Skin cancer knowledge and attitudes in the region of Fez, Morocco: a cross-sectional study